Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Clinical Diabetes
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Spectrum

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Clinical Diabetes
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Spectrum
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
From Research to Practice/Diabetic Kidney Disease

Management of Hypertension in Diabetic Patients With Chronic Kidney Disease

  1. Susan Steigerwalt, MD, FACP
    Diabetes Spectrum 2008 Jan; 21(1): 30-36. https://doi.org/10.2337/diaspect.21.1.30
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Abstract

    In Brief

    Diabetes is associated with markedly increased cardiovascular risk, a risk compounded with imposition of chronic kidney disease (CKD). More than 80% of people with diabetes and CKD have hypertension, and many have an obliterated nocturnal blood pressure “dip,” the normal physiological drop in blood pressure during sleep. Appropriate blood pressure measurement is the Achilles heel of hypertension management, especially in diabetic kidney disease (DKD). This review elaborates on the evidence regarding one of the most important therapeutic targets in DKD, namely, control of blood pressure to < 130/80 mmHg, and provides detailed information about appropriate blood pressure measurement and treatments to best achieve that target.

    An estimated 26 million individuals in the United States have chronic kidney disease (CKD),1 and no less than 11 million have diabetes; an unknown proportion has the metabolic syndrome. The preponderance of those with diabetic kidney disease (DKD) will not progress to kidney failure, but rather will succumb to cardiovascular disease (CVD).2 DKD occurs with frequencies of 30% and 40%, in patients with type 1 and type 2 diabetes, respectively. Blood pressure reduction is the most potent CVD risk reducer in type 2 diabetes, as delineated in the U.K. Prospective Diabetes Study (UKPDS), in which better blood pressure control decreased the onset or degree of albuminuria and micro- and macrovascular complications.3 In addition, blood pressure control is synergized in the context of multiple risk factor intervention. In the Steno 2 study, a small and carefully conducted study of type 2 diabetic patients, impressive CVD risk reductions occurred within 8 years of multidisciplinary interventions including 1) smoking cessation, 2) aspirin use, 3) exercise, 4) tight glycemic control, 5) dietary intervention, 6) lipid treatment, and 7) vitamin and chromium administration.4

    Pathophysiology of Hypertension

    Hypertension in CKD is marked by extracellular fluid volume expansion, sympathetic nervous system activation, and vasoconstrictor accumulations of endothelin and asymmetric dimethylarginine, an endogenous nitric oxide inhibitor.5 Salt sensitivity is common. The prevalence of “non-dipping,” the absence of the naturally occurring blood pressure decline during sleep, increases as CKD worsens from 15% in normal subjects to 75% in those with kidney failure (CKD Stage 5).6 In CKD, a linear correlation exists between hypertension and progressive kidney damage; blood pressure control is crucial to slowing the progression of CKD.7 Diabetes is also associated with increased arterial stiffness from accelerated atherosclerosis, in part the consequence of increased protein glycation attributable to suboptimal glycemic control.8,9

    Evaluation of Hypertensive Patients

    A careful patient history includes the following:

    1. Duration of hypertension

    2. Previously used medications

    3. Review of adverse drug side effects, allergies, or intolerances

    4. Identification of social/support networks (isolation decreases medication adherence)

    5. Smoking, alcohol, or drug history

    6. Current medication reconciliation (reviewing pill bottles and counts to confirm that the patient is taking medications as directed) that includes use of complementary and over-the-counter drugs that may increase blood pressure (Table 1)

    7. Menstrual history (i.e., oligomenorrhea from polycystic ovary syndrome

    8. Exercise and dietary history, including sodium, calcium, and potassium intake

    9. Screening for obstructive sleep apnea (Epworth scale)

    10. Assessment of medication-taking behavior (i.e., adherence)

    View this table:
    • View inline
    • View popup
    • Download powerpoint
    Table 1.

    Agents and Factors That May Increase Blood Pressure

    Systematic review must include symptoms of CVD and secondary forms of hypertension (dyspnea, palpitations, chest pain, and spells). The physical examination should focus on signs of target organ damage, including retinal changes, arterial bruits of renal or other large artery origin, left ventricular hypertrophy (LVH), and signs of secondary hypertension, such as thyromegaly and tremor (thyrotoxicosis) and pink striae (Cushing's disease).

    An initial laboratory evaluation includes measurement of electrolytes, blood urea nitrogen (BUN), serum creatinine with estimation of the glomerular filtration rate (GFR), complete blood count, uric acid, fasting lipid levels of cholesterol and triglycerides, hemoglobin A1c, urinary albumin excretion, and an electrocardiogram. In the future, central aortic pressure and pulse wave velocity measurements will likely complement the tests listed above.10

    Blood pressure measurement modalities

    Office-based blood pressure measurement (OBP). Most randomized, controlled trials continue to rely on careful OBP readings to monitor the response to treatment and outcomes. However, small differences in OBP readings correlate with greater differences in non-OBP readings, as documented in the Heart Outcomes Prevention Evaluation trial.11

    The current seventh Joint National Committee (JNC 7)12 and National Kidney Foundation (NKF) and American Diabetes Association guidelines13,14 base blood pressure control on OBP readings. Furthermore, a growing body of literature documents the importance of non-OBP measurements by patients or by 24-hour ambulatory blood pressure monitoring (ABPM) in diabetes and CKD. Recently, the European Society of Hypertension recommended 24-hour ABPM and home-based readings as an integral part of hypertension evaluation.15 Readers are directed to guidelines that detail appropriate measurement methodology.12,16

    Some automated blood pressure devices have been validated for OBP and record, average, and report data from multiple readings.17 In obese patients whose upper arm measurements preclude appropriate cuff size, wrist monitors, if held at the level of the heart, offer an alternative.

    ABPM. The lack of decline of nocturnal blood pressure, or “non-dipping,” is abnormal but common in patients with CKD and/or proteinuria. This deficit has been linked to cardiovascular events, development of microalbuminuria, progression of CKD, and development of LVH. Yet there are no published trials of renal or cardiovascular outcomes that determine whether blood pressure control, titrated by ABPM, is efficacious.

    Profuse epidemiological data in diabetes, with or without CKD, underscores ABPM's utility, although normal ABPM pressures are lower than OBP readings, i.e., a 24-hour mean blood pressure that mildly exceeds 130/80 mmHg is associated with target organ damage and excessive cardiovascular risk in patients without diabetes. However, standards have not yet been developed for diabetes or CKD.

    In a small but carefully designed study of CKD patients that included patients with diabetes, ABPM more strongly predicted death and progression to kidney failure than OBP.18 The presence of non-dipping predicted mortality and progression to kidney failure. More recently, day- and night-time blood pressure readings predicted prognosis in treated and untreated hypertensive patients. Interestingly, in treated hypertensive patients, outcomes and prognosis were more closely linked to nocturnal blood pressure.19

    Recently, data from normal patients identified those with elevated blood pressure outside of the office but normal ones within it. This condition, known as “masked hypertension,” bears increased cardiovascular risk, and the extent of this phenomenon in CKD and DKD is unknown.20 Finally, ABPM is indicated in resistant hypertension for prognosis and as a guide to therapy, as well as for hypotensive symptoms out of office, white-coat hypertension, and autonomic failure21 (Table 2).

    View this table:
    • View inline
    • View popup
    • Download powerpoint
    Table 2.

    Blood Pressure Thresholds for Definition of Hypertension in People Without Diabetes

    Self- and home-based blood pressure measurement (HBP). HBP is more easily conducted than ABPM but excludes nocturnal blood pressure readings. HBP coincides more closely with 24-hour ABPM than OBP. An initial HBP target of < 130/< 80 mmHg for CKD has proven salutary, with no patients progressing to CKD Stage 5 at the 2-year follow-up in a recent trial.22

    Equally important is the notation that those who engage in HBP adhere to their antihypertensive regimens more fully. HBP more accurately predicts future adverse events than OBP measurement. Based on the Ohasama Study, blood pressure measurements taken in the morning and evening yield additional prognostic information in this regard.23

    American Association of Instrumentation (AAMI)-validated blood pressure cuffs from a variety of manufacturers range in price from ∼ $30 to $100. To most closely simulate ABPM, obtain blood pressure readings twice weekly during initial drug titration, before breakfast, and after the evening meal. After blood pressure has stabilized, obtain readings every 1–2 weeks. Finally, blood pressure cuffs should be calibrated with an accurate, physician-approved oscillometric or, if available, mercury-based blood pressure–measuring device, which are still used in the United States, albeit less frequently due to restrictions governing the use of elemental mercury.

    Pharmacological Treatment of Hypertension in DKD: Initial considerations

    Hypertensive DKD patients, especially African Americans, harbor tremendous risk for kidney failure,2 and intensive therapy is unequivocally protective. Thus, attaining and maintaining recommended blood pressure goals is a clinical mandate. However, DKD patients frequently require three to four agents to achieve blood pressure goals.24–26

    Two agents are advised when the initial blood pressure exceeds the JNC 7 target by > 20/> 10 mmHg. Angiotensin-converting enzyme (ACE)inhibitors and angiotensin 2 receptor blocker (ARB) combinations, especially with diuretics or calcium channel blockers (CCBs), make financial and prescriptive sense (i.e., result in lower daily pill counts and promote medication adherence), particularly given that the DKD”drug load” is extensive.

    CCBs are divided into dihydropyridine and nondihydropyridine classes. Nifedipine and felodipine are examples of the former, and diltiazem and verapamil are examples of the latter.

    ACE inhibitors and ARBs

    Blockade of the renin-angiotensin-aldosterone system (RAAS) in CKD of any type is beneficial. ACE inhibitors are the cornerstone of antihypertensive, renoprotective, cardiovascular, risk-modifying therapy in diabetes; they retard progression of DKD and reduce proteinuria in type 1 and type 2 diabetes.12,13,25,27,28 Side effects include hyperkalemia, acute renal failure, and ACE inhibitor–induced cough. Angioedema occurs rarely, but it is essential to inform patients of this rare life-threatening condition, which occurs primarily in African Americans (< 1 episode per 1,000 drug-years for Caucasians; 4/1,000 drug-years in African Americans).29 ACE inhibitors are lipid neutral and may augment insulin sensitivity, yet they are rarely associated with hypoglycemia. Some posit that ACE inhibitors confer special cardiovascular protective and antiproteinuric effects, whereas others contend that attainment of blood pressure targets is the key to success for any antihypertensive class of drugs.

    ARBs have the largest data set for slowing progression of renal disease in type 2 diabetes. The Irbesartan Diabetic Nephropathy Trial (IDNT)27 and Reduction in End Points in Type 2 Diabetes With the Angiotensin II Antagonist Losartan study trial28 demonstrated renoprotection in established type 2 diabetes with DKD. ARBs in both trials reduced development of heart failure but not of cardiovascular mortality. An IDNT post hoc analysis revealed improved cardiovascular outcomes by achieving systolic blood pressure readings near 120 mmHg.29 In the Losartan for Endpoint Reduction trial, cardiovascular and total mortality benefit in DKD occurred in losartan-treated, but not atenolol-treated, subjects, and this effect coincided with LVH regression.30 An additional benefit of improved glycemic control was found in the ARB-treated group compared to beta blocker therapy with or without concurrent diuretic use.30 ARBs have a much lower incidence of cough and angioedema than ACE inhibitors. To date, no direct, large-scale comparative superiority studies regarding DKD or CKD comparing ACE inhibition to ARB therapy are available.

    A maximally tolerated dose of either an ACE inhibitor or an ARB is always indicated in DKD unless absolutely contravened by side effect or hypersensitivity, even in more advanced stages of CKD. Therefore, maximally tolerated doses of anti-RAAS drugs are the rule, not the exception. Combination therapy composed of an ACE inhibitor and an ARB generally offers a small additive blood pressure–reducing effect of 2–4 mmHg and a synergistic proteinuria-reducing effect.31

    Diuretic agents

    Most DKD patients are volume expanded, necessitating sodium restriction and diuretic treatment. Ideally, these high-risk hypertensive patients are treated with ACE inhibitor-diuretic or ARB-diuretic combinations. The importance of the diuretic component is underscored by the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), in which equivalent protection against coronary heart disease death and nonfatal myocardial infarction was shown in comparisons among mildly hypertensive diabetic subjects and nondiabetic subjects treated with ACE inhibitor, amlodipine, or the diuretic chlorthalidone.26 Chlorthalidone was superior to amlodipine and lisinopril for prevention of heart failure and stroke, perhaps attributable to superior blood pressure control in this treatment arm. African Americans had significantly lower blood pressure and superior outcomes with diuretic monotherapy at the expense of worsened glycemic control, hyperuricemia with or without gout, hypokalemia, and hyponatremia.

    Individuals initiated on diuretics, ACE inhibitors, ARBs, or selective aldosterone receptor antagonists (SARAs) should undergo testing in 1 week for electrolytes and serum creatinine. Chlorthalidone (12.5–25 mg daily) is the preferred thiazide because of its impressive evidence base, yet it is paradoxically prescribed only minimally.26 Patients with an estimated GFR < 40 ml/min/1.73 m2 should be treated with loop diuretics at least twice daily, with dose titration to achieve normal extracellular fluid status.13

    CCBs

    The nondihydropyridine CCBs diltiazem and verapamil are lipid- and glucose-neutral agents and may reduce proteinuria. Dihydropyridine CCBs, such as amlodipine and nifedipine, increase proteinuria when used alone,32 but this adverse effect is abrogated during concurrent ACE inhibitor or ARB administration.

    Notably, amlodipine increased heart failure compared to chlorthalidone, when used alone in patients with diabetes in the ALLHAT.26 The Anglo-Scandinavian Cardiovascular Outcomes Trial (ASCOT), which compared atenolol and a thiazide diuretic to amlodipine and an ACE inhibitor, revealed better outcomes in the latter group, and the best outcomes occurred in the atorvastatin-treated cohort.33 Central aortic pressure was lower with the CCB/ACE inhibitor combination despite similar OBPs.

    Beta blockers

    Beta blockers are used with other drugs and are indicated in patients who have had myocardial infarctions. Their track record in primary prevention of cardiovascular events in hypertension is inferior to other agents including diuretics, and this observation prompted the British Health Service to remove them from its list of first-line antihypertensive agents.34 Concern has been recently raised regarding therapeutic inferiority of atenolol compared to other available beta blockers.35 This author discourages the use of atenolol as antihypertensive therapy, although it was shown to decrease cardiovascular risk and micro- and macrovascular diabetes complications in the UKPDS.36 This author recommends the use of carvedilol or the longer-acting beta blocker metoprolol.

    The beta blocker carvedilol is a combined nonselective beta- and alpha-1 adrenergic inhibitor and is now available as a generic. This agent is associated with improved survival in heart failure.37 In a cohort of hypertensive, type 2 diabetic patients previously treated by ACE inhibitors or ARBs, carvedilol was compared to metoprolol. Carvedilol decreased albumin excretion by 16%, decreased the new onset of microalbuminuria, and increased insulin sensitivity during the course of a 6-month trial.38

    Holistic Treatment of Hypertension in DKD

    After a diagnosis of uncontrolled hypertension (blood pressure > 130/ > 80 mmHg) is established by ABPM, HBP, or OBP, therapy must start or be intensified. Collaborative management by an advanced nurse practitioner, a nurse with expertise in hypertension, and a physician has been shown to improve blood pressure control in diabetic hypertensive patients.39 To provide ultimate CVD risk reduction, multiple risk factor modification is mandatory and includes hypolipidemic therapy and smoking cessation. The latter is highly important because DKD, in the presence of ongoing tobacco use, can sound the death knell for the kidneys and obviates the antihypertensive effects of many blood pressure–reducing drugs.40 Aerobic physical activity with a minimum of 30–45 minutes of brisk walking, 5 days weekly, is strongly encouraged.41 Patients should be counseled to moderate alcohol intake to less than one drink daily for females and two drinks daily for males.

    Any use of alternative or over-the-counter medications should be evaluated. Dietary instructions must emphasize the central importance of limiting sodium to 2,000 mg daily to potentiate the action of antihypertensive and antiproteinuric agents.42 If hyperkalemia is not an issue, the Dietary Approaches to Stop Hypertension diet is appropriate for CKD Stages 1–3,43 and formal dietary consultation for integration of these concepts into the diet of patients with diabetes is crucial. Potassium restriction in CKD Stage 4 is advised, particularly when SARA, ACE inhibitor, or ARB therapy is ongoing. Weight reduction is important, and vigilance for aggravating factors of hypertension is advised.

    Resistant Hypertension

    There are minimal data regarding the frequency of additional secondary causes of hypertension in patients with preexistent CKD, with the exception of obstructive sleep apnea.44 However, if the attainment of target blood pressure has not occurred within 4–6 months of appropriate therapy despite the application of maximally tolerated doses from three to four different classes of antihypertensive drugs including a diuretic, an evaluation for resistance to therapy should be undertaken.45

    This evaluation includes:

    1. Medication reconciliation

    2. Evaluation of medications that may aggravate hypertension (Table 1)

    3. 24-hour urine collection for sodium, potassium, and creatinine

    4. Reduction of sodium intake to < 100 mEq/day

    Evaluations of the following are also recommended:

    1. Sleep apnea or sleep deprivation44

    2. Hypothyroidism

    3. Hyperthyroidism

    4. Cushing's syndrome

    5. Pheochromocytoma

    6. Polycystic ovary syndrome46

    7. Primary aldosteronism in any of its several forms47

    The latter disorder, although present in 10–20% of cases of resistant hypertension, is difficult to diagnose in more advanced CKD because plasma aldosterone may be elevated and renin suppressed. Persistent hypokalemia, hypernatremia, or metabolic alkalosis are clues to the diagnosis. Weight loss and exercise are potent blood pressure–reducing activities, if practiced consistently.

    The choice of additional antihypertensives is limited by a general lack of evidence base in patients with CKD. Recent recommendations by the NKF espouse the use of ACE inhibitors/ARBs, diuretics, and CCBs as the initial three drug classes to treat high blood pressure while instituting and maintaining lifestyle modifications.48 Fourth- and fifth-line agents include central alpha agonists, such as clonidine; pure alpha blockers, such as doxazosin; and direct vasodilators, such as hydralazine or minoxidil. Recent data involving long-acting nitrates for the treatment of isolated systolic hypertension is promising, but a well-informed recommendation cannot be proffered.49

    Unfortunately, none of these medications has a CVD risk reduction database. A careful review of the indications and side effects of these agents before prescribing is necessary, or referral to a hypertension specialist or a physician familiar with these medications is obligatory.

    Available SARAs in the United States include spironolactone and epleronone. These drugs are undergoing study as agents for additional control of proteinuria in CKD Stages 1 and 2.49–51 This drug class is associated with OBP reductions of 5–7 mmHg, significant proteinuria reductions, and urinary albumin excretion reductions of 30–50%. Reversible and mild GFR reductions have been documented. Notably, spironolactone has effectively treated resistant hypertension in patients with normal or near-normal kidney function.52–54 A significant risk of SARA-induced hyperkalemia is evident during coadministration of another anti-RAAS agent (ACE inhibitor or ARB) in advanced DKD, and caution is advised. At a minimum, frequent and careful follow-up of serum potassium levels must be carried out in such circumstances.

    Direct renin inhibitors

    There currently are no data regarding this class of agents in DKD or even nondiabetic CKD. The Aliskiren Trial in Type 2 Diabetics study of aliskiren as a therapeutic add-on to ACE inhibitor or ARB therapy in reducing proteinuria and CV end points is currently enrolling subjects in the United States and Europe.55

    Clinic Follow-up

    Patients should return for follow-up twice monthly until the goal blood pressure is achieved and monthly for 3 months thereafter.56,57 Each office visit represents an opportunity for additional intervention. Medication reconciliation, financial considerations, and practices that increase drug adherence should be reviewed. The use of HBP should be reviewed and encouraged, and blood pressure cuff accuracy should be validated with an AAMI-approved device. Referral to a hypertension specialist is encouraged when blood pressure control requires more than 4–6 months because data from several recent trials show decreased cardiovascular events in patients when blood pressure targets are attained within 6 months.26,46,56 If feasible, confirmatory ABPM should be conducted after HBP and OBP recordings consistently register < 130/80 mmHg. Lastly, parameters such as proteinuria should be monitored in conjunction with electrolytes, BUN, and serum creatinine.

    Summary and Conclusions

    Control of hypertension in DKD requires a collaborative network among patients, primary care providers, endocrinologists, and nephrolgists. Careful blood pressure measurement, a multiple risk factor modification strategy, and persistent and judicious RAAS blockade in combination with diuretics and add-ons should result in good blood pressure control in a majority of patients. Engaging patients and their families through HBP, lifestyle modification, and collaboration with clinic nurses, advanced practice nurses, and clinical pharmacists will facilitate success, thereby reducing the extraordinarily high CVD risk burden of DKD and retarding progression to kidney failure.

    Footnotes

    • Susan Steigerwalt, MD, FACP, is director of the Hypertension Clinic of the Division of Nephrology and Hypertension at St. John Hospital and Medical Center in Detroit, Mich.

    • Note of Disclosure: Dr. Steigerwalt has received research support from Novartis and honoraria for speaking engagements from Novaris, Boehringer-Ingelheim, GlaxoSmithKline, and Sanofi-Aventis. She is a consultant for HomeMedics. These companies make pharmaceutical products or monitoring devices for the treatment of hypertension.

    • American Diabetes Association

    References

    1. ↵
      Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA298 : 2038–2047,2007
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J; National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 36:646 –661, 2000
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      U.K. Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ317 : 703–713,1998
      OpenUrlAbstract/FREE Full Text
    4. ↵
      Gaede P, Vedel P, Larsen N, Jensen GV, Parving H-H, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383 –393, 2003
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      Jacob J, Tsao PS: Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits. Am J Nephrol28 : 224–237,2007
      OpenUrlCrossRefPubMed
    6. ↵
      Paoletti E, Bellino D, Amidone M, Rolla D, Cannella G: Relationship between arterial hypertension and renal damage in chronic kidney disease: insights from ABPM. J Nephrol 19:778 –782, 2006
      OpenUrlPubMedWeb of Science
    7. ↵
      Bidani AK, Griffin KA: Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 44:595 –601, 2004
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG: Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106:2085 –2090, 2002
      OpenUrlAbstract/FREE Full Text
    9. ↵
      Gross ML, Dikow R, Ritz E: Diabetic nephropathy: recent insights into the pathophysiology and progression of diabetic nephropathy. Kidney Int94 (Suppl.):S50 –S53, 2005
      OpenUrl
    10. ↵
      Ibsen H, Jeppesen J: Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation113 : 664–670,2006
      OpenUrlAbstract/FREE Full Text
    11. ↵
      Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of CV disease in HOPE. Ann Intern Med134 : 629–636,2001
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560 –2572, 2003
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (Suppl. 1):S1 –S290, 2004
      OpenUrlPubMed
    14. ↵
      KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49 (Suppl. 2):S1 –S179, 2007
      OpenUrl
    15. ↵
      Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology: 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. J Hypertens 25:1105 –1187, 2007
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ: Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111:697 –716, 2005
      OpenUrlAbstract/FREE Full Text
    17. ↵
      Beckett L, Godwin M: The BpTRU automatic blood pressure monitor compared to 24 hour ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. BMC Cardiovasc Disord28 : 18,2005
      OpenUrl
    18. ↵
      Agarwal R, Andersen MJ: Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int69 : 1175–1180,2006
      OpenUrlCrossRefPubMedWeb of Science
    19. ↵
      Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E, Staessen JA; International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes investigators: Accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 370:1219 –1229, 2007
      OpenUrlCrossRefPubMedWeb of Science
    20. ↵
      Pickering TG, Davidson K, Gerin W, Schwartz JE: Masked hypertension. Hypertens 40:795 –795, 2002
      OpenUrlFREE Full Text
    21. ↵
      White WB: Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment. J Clin Hypertens 9 (Suppl. 1): 25–30,2007
      OpenUrl
    22. ↵
      Agarwal R, Andersen MJ: Clinic versus home blood-pressure measurements as a predictor of outcomes in chronic kidney disease. Nature Clin Pract Nephrol 9:474 –475, 2006
      OpenUrl
    23. ↵
      Asayama K, Ohkubo T, Kikuya M, Obara T, Metoki H, Inoue R, Hara, A, Hirose T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y: Prediction of stoke by home “morning” versus “evening” blood pressure values: the Ohasama study. Hypertens 48:737 –743, 2006
      OpenUrlAbstract/FREE Full Text
    24. ↵
      Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285:685 –688, 1982
      OpenUrlAbstract/FREE Full Text
    25. ↵
      Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. N Engl J Med329 : 1456–1462,1993
      OpenUrlCrossRefPubMedWeb of Science
    26. ↵
      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288:2981 –2997, 2002
      OpenUrlCrossRefPubMedWeb of Science
    27. ↵
      Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med345 : 851–860,2001
      OpenUrlCrossRefPubMedWeb of Science
    28. ↵
      Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861 –869, 2001
      OpenUrlCrossRefPubMedWeb of Science
    29. ↵
      Sica DA, Black DR: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? J Clin Hypertens 4:375 –380, 2002
      OpenUrlCrossRef
    30. ↵
      Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomized trial against atenolol. Lancet359 : 995–1003,2002
      OpenUrlCrossRefPubMedWeb of Science
    31. ↵
      Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM: Renin-angiotensin system and cardiovascular risk. Lancet369 : 1208–1219,2007
      OpenUrlCrossRefPubMedWeb of Science
    32. ↵
      Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 65:1991 –2002, 2004
      OpenUrlCrossRefPubMedWeb of Science
    33. ↵
      Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366 : 895–906,2005
      OpenUrlCrossRefPubMedWeb of Science
    34. ↵
      British Health Service National Institute for Health and Clinical Excellence: Management of hypertension in adults in primary care [article online]. Available at http://www.nice.org.uk/CG034.html. Accessed 2 December 2007
    35. ↵
      Lindholm LH, Carlberg B, Samuelsson O: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545 –1553, 2005
      OpenUrlCrossRefPubMedWeb of Science
    36. ↵
      U.K. Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713 –720, 1998
      OpenUrlAbstract/FREE Full Text
    37. ↵
      Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med126 : 955–959,1997
      OpenUrlCrossRefPubMedWeb of Science
    38. ↵
      Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators: Metabolic effects of carvedilol versus metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292:2227 –2236, 2004
      OpenUrlCrossRefPubMedWeb of Science
    39. ↵
      Canzanello VJ, Jensen PL, Schwartz LL, Worra JB, Klein LK: Improved blood pressure control with a physician-nurse team and home blood pressure measurement. Mayo Clin Proc 80:31 –36, 2005
      OpenUrlCrossRefPubMedWeb of Science
    40. ↵
      Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M: Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17:126 –131, 1994
      OpenUrlAbstract/FREE Full Text
    41. ↵
      Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A; American College of Sports Medicine; American Heart Association: Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 116:1081 –1093, 2007
      OpenUrlCrossRefPubMedWeb of Science
    42. ↵
      Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, Weir MR: An indepth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol 26:268 –275, 2006
      OpenUrlCrossRefPubMed
    43. ↵
      Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med336 : 1117–1124,1997
      OpenUrlCrossRefPubMedWeb of Science
    44. ↵
      Sim JJ, Rasgon SA, DeRose SF: Sleep apnea and hypertension: prevalence in chronic kidney disease. J Clin Hypertens 9:837 –841, 2007
      OpenUrl
    45. ↵
      Moser M, Cushman W, Handler J: Resistant or difficult-to-treat hypertension. J Clin Hypertension 8:434 –440, 2006
      OpenUrl
    46. ↵
      Reckelhoff JF: Polycystic ovary syndrome, androgens and hypertension. Hypertension 49:1220 –1221, 2007
      OpenUrlFREE Full Text
    47. ↵
      Plouin P-F, Amar L, Chatellier G: Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically-correctable aldosterone-dependent hypertension. Nephrol Dial Transplant 19:774 –777, 2004
      OpenUrlFREE Full Text
    48. ↵
      American Diabetes Association: Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association.30 : S48–S65,2007
      OpenUrl
    49. ↵
      Stokes GS, Bune AJ, Huon N, Barin ES: Long-term effectiveness of extended-release nitrate for the treatment of systolic hypertension. Hypertension45 : 380–384,2005
      OpenUrlAbstract/FREE Full Text
    50. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1:256 –262, 2006
      OpenUrlAbstract/FREE Full Text
    51. ↵
      Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28:2106 –2112, 2005
      OpenUrlAbstract/FREE Full Text
    52. ↵
      van den MeirackerAH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F: Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 24:2285 –2292, 2006
      OpenUrlCrossRefPubMedWeb of Science
    53. Calhoun DA: Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens9 (Suppl. 1):19 –24, 2007
      OpenUrl
    54. ↵
      Lane DA, Shah S, Beevers DG: Low-dose spironolactone in management of resistant hypertension: a surveillance study. J Hypertens25 : 891–894,2007
      OpenUrlCrossRefPubMedWeb of Science
    55. ↵
      National Institutes of Health: Aliskiren trial in type 2 diabetes using cardiovascular and renal disease endpoints [article online]. Available from http://clinicaltrials.gov/ct2/show/NCT00549757?term=ALTITUDE+aliskiren&rank=1. Accessed 1 December 2007
    56. ↵
      Wiederkehr M, Toto R, Fenves AZ, Ram CVS: Hypertension and the kidney. Semin Nephrol 25:236 –245, 2005
      OpenUrlPubMed
    57. ↵
      Julius S, Kjeldsen SE, Weber M, for the VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet363 : 2022–2031,2004
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top

    In this Issue

    January 2008, 21(1)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes Spectrum.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Management of Hypertension in Diabetic Patients With Chronic Kidney Disease
    (Your Name) has forwarded a page to you from Diabetes Spectrum
    (Your Name) thought you would like to see this page from the Diabetes Spectrum web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Management of Hypertension in Diabetic Patients With Chronic Kidney Disease
    Susan Steigerwalt
    Diabetes Spectrum Jan 2008, 21 (1) 30-36; DOI: 10.2337/diaspect.21.1.30

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Management of Hypertension in Diabetic Patients With Chronic Kidney Disease
    Susan Steigerwalt
    Diabetes Spectrum Jan 2008, 21 (1) 30-36; DOI: 10.2337/diaspect.21.1.30
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Pathophysiology of Hypertension
      • Evaluation of Hypertensive Patients
      • Blood pressure measurement modalities
      • Pharmacological Treatment of Hypertension in DKD: Initial considerations
      • ACE inhibitors and ARBs
      • Diuretic agents
      • CCBs
      • Beta blockers
      • Holistic Treatment of Hypertension in DKD
      • Resistant Hypertension
      • Direct renin inhibitors
      • Clinic Follow-up
      • Summary and Conclusions
      • Footnotes
      • References
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Anemia in Patients With Chronic Kidney Disease
    • Secondary Hyperparathyroidism and Chronic Kidney Disease
    Show more From Research to Practice/Diabetic Kidney Disease

    Similar Articles

    Navigate

    • Current Issue
    • Papers in Press
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes
    • Diabetes Care
    • Clinical Diabetes
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Spectrum Print ISSN: 1040-9165, Online ISSN: 1944-7353.